Early immune-suppressing treatment for VKH eye disease
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial studies giving immune-suppressing treatment early in Vogt-Koyanagi-Harada (VKH) disease to see if it improves outcomes. It may help people reduce ongoing eye inflammation if they qualify and can be followed for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute Vogt-Koyanagi-Harada (VKH) disease
- You are willing and able to work with the study team (be “collaborative”)
- You can agree to have at least 1 year of follow-up visits or check-ins
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tacrolimus eye drops can reduce the symptoms of vernal keratoconjunctivitis (a severe eye allergy) in children aged 5 to 15. If effective, the treatment could provide a new option to control this uncomfortable condition.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
This trial tests whether giving a steroid can prevent severe immune overreactions in people starting HIV treatment who have had an AIDS-related infection. It aims to reduce complications and improve outcomes.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Hear when a new Vogt Koyanagi Harada Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.